Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prescription psychostimulants for the treatment of amphetamine-type stimulant use disorder: A systematic review and meta-analysis of randomized placebo-controlled trials.
Sharafi H, Bakouni H, McAnulty C, Drouin S, Coronado-Montoya S, Bahremand A, Bach P, Ezard N, Le Foll B, Schütz CG, Siefried KJ, Tardelli VS, Ziegler D, Jutras-Aswad D. Sharafi H, et al. Among authors: mcanulty c. Addiction. 2024 Feb;119(2):211-224. doi: 10.1111/add.16347. Epub 2023 Oct 25. Addiction. 2024. PMID: 37880829 Review.
Buprenorphine/naloxone and methadone effectiveness for reducing craving in individuals with prescription opioid use disorder: Exploratory results from an open-label, pragmatic randomized controlled trial.
McAnulty C, Bastien G, Eugenia Socias M, Bruneau J, Foll BL, Lim R, Brissette S, Ledjiar O, Marsan S, Talbot A, Jutras-Aswad D; OPTIMA Research Group within the Canadian Research Initiative in Substance Misuse. McAnulty C, et al. Drug Alcohol Depend. 2022 Oct 1;239:109604. doi: 10.1016/j.drugalcdep.2022.109604. Epub 2022 Aug 17. Drug Alcohol Depend. 2022. PMID: 36037586 Free article. Clinical Trial.
Efficacy of ketamine intervention to decrease alcohol use, cravings, and withdrawal symptoms in adults with problematic alcohol use or alcohol use disorder: A systematic review and comprehensive analysis of mechanism of actions.
Garel N, McAnulty C, Greenway KT, Lesperance P, Miron JP, Rej S, Richard-Devantoy S, Jutras-Aswad D. Garel N, et al. Among authors: mcanulty c. Drug Alcohol Depend. 2022 Oct 1;239:109606. doi: 10.1016/j.drugalcdep.2022.109606. Epub 2022 Aug 20. Drug Alcohol Depend. 2022. PMID: 36087563 Free article. Review.
Effects of Buprenorphine/Naloxone and Methadone on Depressive Symptoms in People with Prescription Opioid Use Disorder: A Pragmatic Randomised Controlled Trial.
Bastien G, McAnulty C, Ledjiar O, Socias ME, Le Foll B, Lim R, Hassan AN, Brissette S, Marsan S, Talbot A, Jutras-Aswad D; OPTIMA Research Group within the Canadian Research Initiative in Substance Misuse. Bastien G, et al. Among authors: mcanulty c. Can J Psychiatry. 2023 Aug;68(8):572-585. doi: 10.1177/07067437221145013. Epub 2022 Dec 14. Can J Psychiatry. 2023. PMID: 36519188 Free PMC article. Clinical Trial.
Differential effect of cannabis use on opioid agonist treatment outcomes: Exploratory analyses from the OPTIMA study.
Elkrief L, Bastien G, McAnulty C, Bakouni H, Hébert FO, Socias ME, Le Foll B, Lim R, Ledjiar O, Marsan S, Brissette S, Jutras-Aswad D; OPTIMA Research Group within the Canadian Research Initiative in Substance Misuse. Elkrief L, et al. Among authors: mcanulty c. J Subst Use Addict Treat. 2023 Jun;149:209031. doi: 10.1016/j.josat.2023.209031. Epub 2023 Mar 30. J Subst Use Addict Treat. 2023. PMID: 37003540 Free article. Clinical Trial.
Associations of methadone and buprenorphine-naloxone doses with unregulated opioid use, treatment retention, and adverse events in prescription-type opioid use disorders: Exploratory analyses of the OPTIMA study.
Bakouni H, McAnulty C, Tatar O, Socias ME, Le Foll B, Lim R, Ahamad K, Jutras-Aswad D; OPTIMA Research Group within the Canadian Research Initiative in Substance Misuse. Bakouni H, et al. Among authors: mcanulty c. Am J Addict. 2023 Sep;32(5):469-478. doi: 10.1111/ajad.13439. Epub 2023 Jun 12. Am J Addict. 2023. PMID: 37308805 Clinical Trial.
Impact of Depressive Symptom Severity on Buprenorphine/Naloxone and Methadone Outcomes in People With Prescription-Type Opioid Use Disorder: Results From a Pragmatic Randomized Controlled Trial.
Bastien G, Abboud A, McAnulty C, Elkrief L, Ledjiar O, Socias ME, Le Foll B, Bahji A, Brissette S, Marsan S, Jutras-Aswad D. Bastien G, et al. Among authors: mcanulty c. J Dual Diagn. 2024 Apr 5:1-12. doi: 10.1080/15504263.2024.2329267. Online ahead of print. J Dual Diagn. 2024. PMID: 38580298
Mediating effect of craving on the impact of buprenorphine/naloxone and methadone treatment on opioid use: Results from a randomized controlled trial.
McAnulty C, Bastien G, Ledjiar O, Eugenia Socias M, Le Foll B, Lim R, Jutras-Aswad D; OPTIMA Research Group within the Canadian Research Initiative in Substance Misuse. McAnulty C, et al. Addict Behav. 2024 Jul;154:108023. doi: 10.1016/j.addbeh.2024.108023. Epub 2024 Mar 27. Addict Behav. 2024. PMID: 38579594 Clinical Trial.
Prevalence of mutations in common tumour types in Northern England and comparable utility of national and international Trial Finders.
Rae S, Plummer E, Fitzgerald L, Hogarth L, Bridgewood A, Brown-Schofield L, Graham J, Haigh S, McAnulty C, Drew Y, Haris N, Bashir S, Plummer R, Greystoke A. Rae S, et al. Among authors: mcanulty c. J Cancer Res Clin Oncol. 2023 Dec;149(18):16355-16363. doi: 10.1007/s00432-023-05365-y. Epub 2023 Sep 13. J Cancer Res Clin Oncol. 2023. PMID: 37702806 Free PMC article.
Detection of constitutional mismatch repair deficiency in children and adolescents with acute lymphoblastic leukemia.
Gallon R, Phelps R, Betts L, Hayes C, Masic D, Irving JAE, McAnulty C, Saha V, Vora A, Wimmer K, Motwani J, Macartney C, Burn J, Jackson MS, Moorman AV, Santibanez-Koref M. Gallon R, et al. Among authors: mcanulty c. Leuk Lymphoma. 2023 Jan;64(1):217-220. doi: 10.1080/10428194.2022.2131412. Epub 2022 Oct 22. Leuk Lymphoma. 2023. PMID: 36272172 No abstract available.
16 results